Changes in the ratio of urinary α1-microglobulin to ulinastatin levels in patients with Alzheimer-type dementia and vascular dementia

Abstract Relationships between urinary levels of α1-microglobulin (α1M) and ulinastatin (UT) in patients with dementia were investigated. There were no significant differences in α1M and UT levels and α1M: UT ratios among three groups: age-matched control subjects, patients with either Alzheimer-type senile dementia (ATD) or vascular dementia (VD). Although a positive correlation was established between α1M and UT levels in these groups, the regression of the demented patients differed significantly from that of controls ( P <0.05). A tendency towards a negative correlation between α1M: UT ratios and the levels of severity or duration of the disease was displayed in the ATD group, whereas a tendency toward a positive correlation between α1M: UT ratios and the levels of severity was observed in the VD group. These results suggest that changes in the relationships between urinary levels of α1M and UT may provide a useful biochemical index for diagnoses of ATD and VD.     

Dose-response differences in the ability of ramipril to improve retention in diabetic mice

Ramipril blocks the conversion of angiotensin I to II. The literature indicates that diabetes is often associated with mild impairment of learning and memory. The study reports the effects of ramipril on memory retention in diabetic and non-diabetic mice. Mice were made diabetic by an injection of streptozocin. After overt signs of diabetes were present, diabetic or vehicle-treated mice were partially trained on a footshock active avoidance task. Immediately after training, ramipril (0.5–1.5 mg/kg s.c.) was administered and retention was tested by continuing training one week later until mice avoided footshock on five out of six trails. The results indicate that ramipril enhanced retention of both diabetic and control mice but it required about 5 times as much ramipril in diabetic as control mice to achieve the same effect on retention. Increased sensitivity to angiotensin II may play a role in cognitive impairment in diabetes.     

夹竹桃甙对Na~+、K~+-ATP酶抑制的动力学研究

本文对夹竹桃甙抑制Na~+、K~+-ATP酶的动力学作了探讨,并与乌本甙的作用进行了比较。结果表明:夹竹桃甙抑制Na~+、K~+-ATP酶,在Na~+、K~+浓度改变对均为非竞争性抑制,Na~+/K~+比例6:1时,为混合性抑制,而ATP对夹竹桃甙的作用几无影响。     

石杉碱甲类似物的研究II.N-甲基吡啶酮石杉碱甲类似物的合成

石杉碱甲(1)是从中草药石杉属植物千层塔(Lycopodium serratum Thunb.)中分得的一种高效可逆的乙酰胆碱酯酶抑制剂,临床试验证实它对早老性痴呆症有显著疗效。本文报道N-甲基吡啶酮石杉碱甲类似物2和3的合成。2-甲氧基-5-甲氧羰基-11-亚甲基-5,9-甲撑环辛-7-烯并吡啶(9)在乙腈中用三甲基氯硅烷和碘化钠选择性脱保护以定量的产率得吡啶酮10,再用甲醇钠和碘甲烷甲基化得N-甲基吡啶酮11,11经碱性水解,Curtius重排和氨基的脱保护得N-甲基吡啶酮石杉碱甲类似物2。通过类似的途径从中间体2-甲氧基-5-甲氧羰基-7-甲基-11-酮-5,9-甲撑环辛-7-烯并吡啶(14)合成了类似物3。类似物2和3的乙酰胆碱酯酶抑制活性均低于天然石杉碱甲。     

缬沙坦与苯那普利拉对SHR肾小球系膜细胞的保护作用

目的：观察ARB－valsartan及ACEI－benazeprilat能否抑制由AngⅡ、PDGF引起的SHR肾小球系膜细胞的增殖与肥大。且比较单用时作用孰强孰弱，联合应用后有无协同效应。方法；采用经典SHR系膜细胞培养技术，细胞中加入各种因子和（或）药物，以^3H-leucine或^3H-thymidine掺入后的cpm值反映蛋白或DNA合成。采用t test检验差异的显著性。结果：1、系膜细胞在AngⅡ、PDGF刺激后引起的增殖与肥大，均可被valsartan及benazeprilat抑制。2、比较发现单一用药在同一浓度下，valsartan较benazeprilat能更有效地抑制细胞的增殖与肥大。3、联合用药在同一浓度valsartan benazeprilat均比单用valsartan或benazeprilat效果明显。结论：1、valsartan与benazeprilat均能抑制SHR系膜细胞的增殖与肥大。2、valsartan在抗系膜细胞增殖与肥大作用稍强于benazeprilat。3、在一定浓度条件下联合用药对抗系膜细胞的增殖与肥大作用，较单一用药效果明显。     

Serum markers for fibrosis and plasma transforming growth factor-β1 in patients with hepatocellular carcinoma in comparison with patients with liver cirrhosis

In order to elucidate collagen metabolism in hepatocellular carcinoma (HCC) tissue, we compared levels of different potential markers of collagen metabolism and plasma transforming growth factor-β₁ in patients with HCC and in patients with liver cirrhosis. Serum levels of prolyl hydroxylase and the tissue inhibitor of metalloproteinase-1 in patients with HCC were significantly higher than those in patients with liver cirrhosis and increased with the size of the HCC tumour, whereas the serum levels of procollagen type III propeptide and type IV collagen 7S domain were similar in the two groups. In HCC, the increased plasma transforming growth factor-β₁ levels were closely correlated with serum levels of prolyl hydroxylase and the tissue inhibitor of metalloproteinase-1. These findings suggest that, in HCC tissue, the intracellular biosynthesis of collagen is enhanced, whereas the secretion of procollagen is disturbed and the degradation of collagen is suppressed by the excess production of the tissue inhibitor of metalloproteinase-1. The results also suggest that plasma transforming growth factor-β₁ plays an important role in the altered metabolism of collagen in HCC.     

Immunohistochemical localization of tissue factor pathway inhibitor-1 (TFPI-1), a Kunitz proteinase inhibitor, in Alzheimer''s disease

Senile plaques in Alzheimer's disease (AD) are composed principally of Aβ, a 4 kDa fragment of the amyloid precursor protein (APP). Longer forms of APP which contain a Kunitz proteinase inhibitor (KPI) domain are elevated in aged and in AD brains. Tissue factor pathway inhibitor-1 (TFPI) contains three tandem KPI domains and has been well characterized for its role as a natural anticoagulant in the extrinsic coagulation pathway. Functionally, the first two KPI domains of TFPI bind and inhibit the activity of factor Xa and VIIa respectively. In addition, TFPI and APP-KPI share a common clearance mechanism through the low density lipoprotein receptor-related protein (LRP). As part of an ongoing study of the role of KPI-containing proteins in AD, the current study examines TFPI localization in the brain. We report here that TFPI is immunohistochemically localized to microglia in both AD and non-AD individuals and is localized to some senile plaques in AD. Western blot analyses indicate that the amount of TFPI is elevated in frontal cortex samples from AD brains. We propose that TFPI may play a cell specific role in proteinase regulation in the brain.     

肝素对患感染性疾病的新生儿组织因子途径抑制物影响的观察

目的:观察肝素对患感染性疾病的新生儿组织因子途径抑制物(TFPI)的影响。方法:采用酶联免疫吸附试验(ELISA)法检测了32例患感染性疾病的新生儿在使用肝素前和使用肝素后30～45分钟、6小时血浆TFPI的变化,并与患儿对照组、正常对照组及文献进行比较。结果:患儿治疗组使用肝素后30～45分钟血浆TFPI水平明显增高(t=3.953,P<0.001),6小时血浆TFPI又几乎降至用药前水平(t=0.141,P<0.05)。结论:新生儿对肝素的反应与成人不同。     

MMP-9和TIMP-1在实验性肺气肿大鼠肺组织中的表达及其意义

目的研究基质金属蛋白酶(MMP-9)及其组织抑制因子(TIMP-1)在弹性蛋白酶所致肺气肿大鼠肺组织中的表达.方法雄性Wistar大鼠20只,随机分为两组:正常对照组和肺气肿模型组,每组10只.模型组大鼠气管内滴入弹性蛋白酶复制肺气肿模型.25d后,观察各组大鼠肺组织的病理改变,免疫组化方法观察肺组织MMP-9和TIMP-1中的蛋白表达情况.结果肺气肿模型组MMP-9和TIMP-1的表达与正常对照组相比明显增强(P＜0.01),且MMP-9/TIMP-1比值失衡.结论MMP-9/TIMP-1失衡在肺气肿形成中起重要作用.     

雅施达治疗老年人充血性心力衰竭的临床疗效观察

目的 :观察雅施达 (培哚普利 )治疗老年人充血性心力衰竭 (CHF)的临床疗效。方法 :5 9例经常规洋地黄、利尿剂、血管扩张药等治疗效果欠佳的CHF老年患者 ,给予口服雅施达 2mg/d4mg/d ,治疗 4周 6周。观察治疗前后心率、心胸比、血压、左室舒张末期内径、左室射血分数以及心功能变化。结果 :治疗后心率、血压、心胸比以及左室舒张末期内径与治疗前比较均明显下降 (P <0 .0 5 )。左室射血分数增加 (P <0 .0 5 ) ,心功能改善 1级 2级。药物副作用少 ,患者耐受性好。结论 :雅施达治疗老年人CHF疗效好 ,副作用少 ,是理想的治疗药物